Member Contact: Paul Carboon
Position: Founder and CEO
Industry: Biotech & Pharmaceuticals
Microbio is developing InfectID, a revolutionary pathogen identification test – fast, inexpensive, highly sensitive and adaptable to address different target pathogens. InfectID uses real-time PCR to home in on a pathogen’s DNA ‘fingerprint’, found at a specific point in its genetic code. Microbio’s initial focus has been to develop a sepsis pathogen identification blood test with no need to pre-culture. Microbio is also working to develop a rapid, inexpensive and sensitive COVID-19 test using the same technology.